Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Oregon Health and Science University
Sponsor:
Collaborator:
University of Pittsburgh
Information provided by (Responsible Party):
Melanie B Gillingham, Oregon Health and Science University
ClinicalTrials.gov Identifier:
NCT01379625
First received: June 21, 2011
Last updated: June 17, 2014
Last verified: June 2014
  Purpose

Humans eat long-chain fat in their diet and use it for energy during exercise and during periods of fasting. Patients with long-chain fatty acid oxidation disorders cannot use dietary fat for energy. They sometimes develop muscle breakdown, and severe pain with exercise or illness. They can also develop a heart that does not function properly. These patients are tired and expend less energy than people who do not have a long-chain fatty acid oxidation disorder. However, they can use a supplement oil called medium chain triglyceride or MCT. This study will determine if a new experimental oil called Triheptanoin can decrease the muscle pain and increase the heart function and the amount of energy in patients with long-chain fatty acid oxidation disorders. Funding source - FDA's OOPD


Condition Intervention Phase
Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency
Carnitine Palmitoyltransferase 2 (CPT2) Deficiency
Mitochondrial Trifunctional Protein (TFP) Deficiency
Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) Deficiency
Drug: Triheptanoin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Phase 2 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders

Resource links provided by NLM:


Further study details as provided by Oregon Health and Science University:

Primary Outcome Measures:
  • Energy Expenditure [ Time Frame: change from baseline after 4 months of treatment ] [ Designated as safety issue: No ]
    Total energy expenditure will be measured by doubly labeled water and resting energy expenditure will be measured by indirect calorimetry at baseline and again after 4 months of either MCT or trihpetanoin treatment.


Secondary Outcome Measures:
  • Exercise heart rate [ Time Frame: change from baseline to 4 months of treatment ] [ Designated as safety issue: No ]
    Subjects will complete a submaximal treadmill exercise study at baseline. Exercise heart heart, ventilation and perceived exertion will be measured. Subjects will be randomized to MCT or triheptanoin supplementation for 4 months. At the end of treatment, the exercise test will be repeated keeping work performed constant. Change in exercise heart rate, ventilation and exertion will be compared between groups.


Estimated Enrollment: 32
Study Start Date: September 2011
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Medium Chain Triglyceride (MCT)
Subjects randomized to consume 20% of energy from MCT
Drug: Triheptanoin
Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
Other Names:
  • IND 113386
  • C7
Experimental: Triheptanoin
Subject randomized to consume 20% of energy from triheptanoin.
Drug: Triheptanoin
Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
Other Names:
  • IND 113386
  • C7

Detailed Description:

Recruitment: Patients with a long-chain fatty acid oxidation disorder will be recruited through our clinic, past research participants, a patient support website, and recruitment letters mailed to physicians around the US. We will enroll 16 subjects at OHSU and 16 subjects at the University of Pittsburgh, age 7 to 40, with a disorder in fatty acid oxidation.

Procedures: Subjects will be admitted to the clinical research center for 4 days. They will collect all their urine for 24 hours. Heart function will be measured using ultrasound an electrocardiogram (ECG). The motion of the heart will be measured by magnetic resonance imaging (MRI). For this test, the patient lies in the magnetic field of the MRI machine in the Advanced Imaging Resource Center (AIRC) for about 45 minutes. The amount of muscle and fat in the whole body and inside the liver and muscle will be measured by MRS and by dual X-ray absorptiometry (DEXA). Subjects will walk on a treadmill for about 45 minutes. The amount of Calories they use, their heart rate, and if they burn fat or carbohydrates will be measured. Blood samples will be collected before and after exercise. A meal test will be used to determine how much fat they burn. The subjects will drink a liquid breakfast with a stable isotope labeled fat in the breakfast. Breath and blood samples will be collected before and after the meal. The amount Calories burned by each subject will be measured when they are at rest on a bed by indirect calorimetry. The amount of Calories burned by subjects when they are doing their routine daily activities will be measured at home by doubly labeled water. All of these tests will be done at baseline. Then, subjects will be randomly assigned to consume MCT (current standard of care) or triheptanoin at 20% of their estimated Calorie needs for 4 months. The subject and/or the parent will be taught how to use the supplement oil in their diet for cooking and baking. The subject will be sent home and the oil will be shipped to their home. The study coordinator will call the subject or subject's guardian each week to monitor the subject's diet, potential side effects and assist with diet planning. At the end of 4 months, all of the baseline tests will be repeated.

Triheptanoin is experimental oil. It is a clear, odorless oil that can be mixed with foods and used in cooking. Almost all oils are made from even chains of carbon molecules. Triheptanoin is different because the carbon chains are odd in number. The co-investigator of this study at the University of Pittsburgh, Dr. Jerry Vockely, holds an IND for the prescription, and use of triheptanoin in humans (IND 106011).

Data Analysis: The change in exercise ability, heart function, Calories used and body fat after 4 months will be compared between subjects randomized to MCT versus triheptanoin.

  Eligibility

Ages Eligible for Study:   7 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed diagnosis of Very long-chain acylCoA dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase 2 (CPT2) Deficiency, Mitochondrial Trifunctional Protein (TFP) Deficiency, or Long-chain 3 hydroxyacylCoA dehydrogenase (LCHAD) deficiency
  • > 7 years
  • Ability to travel to CRC to participate
  • Ability to follow protocol

Exclusion Criteria:

  • Hgb < 10 g/dl
  • Peripheral neuropathy that limits ability to complete treadmill studies
  • Inclusion in another research study that alters macronutrient intake
  • Pregnant females
  • history of myocardial infarction or cardiovascular disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01379625

Contacts
Contact: Julie Martin, MS, RD 503-494-5313 martijul@ohsu.edu

Locations
United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Julie Martin, MS    503-494-5313    martijul@ohsu.edu   
Contact: Melanie B Gillingham, PhD    503-494-1682    gillingm@ohsu.edu   
Principal Investigator: Melanie B Gillingham, PhD         
Sub-Investigator: Cary O Harding, MD         
United States, Pennsylvania
University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Contact: Stephanie DeWard, MS, CGC    412-692-5232    stephanie.deward@chp.edu   
Principal Investigator: Gerard Vockley, MD, PhD         
Sponsors and Collaborators
Oregon Health and Science University
University of Pittsburgh
Investigators
Principal Investigator: Melanie B Gillingham, PhD Oregon Health and Science University
  More Information

No publications provided

Responsible Party: Melanie B Gillingham, Assistant Professor, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT01379625     History of Changes
Other Study ID Numbers: FD003895
Study First Received: June 21, 2011
Last Updated: June 17, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Oregon Health and Science University:
fatty acid oxidation
triheptanoin
long-chain fatty acid oxidation disorders
LCHADD
VLCADD
CPT2
TFP

ClinicalTrials.gov processed this record on July 20, 2014